Academic literature on the topic 'Cancer-On-Chip'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cancer-On-Chip.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Cancer-On-Chip":
Torisawa, Yu-suke, Yuta Mishima, and Shin Kaneko. "Developing thymus-on-a-chip and cancer-on-a-chip for cancer immunotherapy." Impact 2019, no. 2 (March 18, 2019): 33–35. http://dx.doi.org/10.21820/23987073.2019.2.33.
Zhang, Xiaojun, Mazharul Karim, Md Mahedi Hasan, Jacob Hooper, Riajul Wahab, Sourav Roy, and Taslim A. Al-Hilal. "Cancer-on-a-Chip: Models for Studying Metastasis." Cancers 14, no. 3 (January 27, 2022): 648. http://dx.doi.org/10.3390/cancers14030648.
Lee, I.-Chi. "Cancer-on-a-chip for Drug Screening." Current Pharmaceutical Design 24, no. 45 (April 16, 2019): 5407–18. http://dx.doi.org/10.2174/1381612825666190206235233.
Hao, Hsu-Chao, and Da-Jeng Yao. "Detection of Cancer Cells on a Chip." Current Topics in Medicinal Chemistry 15, no. 15 (May 22, 2015): 1543–50. http://dx.doi.org/10.2174/1568026615666150414150950.
Elmusrati, Mohammed, and Nureddin Ashammakhi. "Cancer-on-a-Chip and Artificial Intelligence." Journal of Craniofacial Surgery 29, no. 7 (October 2018): 1682–83. http://dx.doi.org/10.1097/scs.0000000000004703.
Komen, Job, Sanne M. van Neerven, Elsbeth G. B. M. Bossink, Nina E. de Groot, Lisanne E. Nijman, Albert van den Berg, Louis Vermeulen, and Andries D. van der Meer. "The Effect of Dynamic, In Vivo-like Oxaliplatin on HCT116 Spheroids in a Cancer-on-Chip Model Is Representative of the Response in Xenografts." Micromachines 13, no. 5 (May 6, 2022): 739. http://dx.doi.org/10.3390/mi13050739.
Zuchowska, Agnieszka, and Sandra Skorupska. "Multi-organ-on-chip approach in cancer research." Organs-on-a-Chip 4 (December 2022): 100014. http://dx.doi.org/10.1016/j.ooc.2021.100014.
Fey, M. F. "The impact of chip technology on cancer medicine." Annals of Oncology 13 (October 2002): 109–13. http://dx.doi.org/10.1093/annonc/mdf647.
Sabour, Andrew F., Seung-min Park, Jun Ho Son, and Luke P. Lee. "An On-Chip Pcr Approach Enabling Cancer Diagnosis." Biophysical Journal 106, no. 2 (January 2014): 618a. http://dx.doi.org/10.1016/j.bpj.2013.11.3420.
MASUDA, Taisuke, Miyako NIIMI, Hayao NAKANISHI, and Fumihito ARAI. "7B21 On-chip Cancer Diagnosis for Early Recognition of Gastric Cancer." Proceedings of the Bioengineering Conference Annual Meeting of BED/JSME 2012.24 (2012): _7B21–1_—_7B21–2_. http://dx.doi.org/10.1299/jsmebio.2012.24._7b21-1_.
Dissertations / Theses on the topic "Cancer-On-Chip":
Chatagnon, Amandine. "Spécificité de liaison et de répression de la " Methyl-CpG-Binding Domain protein 2 " (MBD2) : identification de gènes cibles impliqués dans les cancers." Phd thesis, Université Claude Bernard - Lyon I, 2009. http://tel.archives-ouvertes.fr/tel-00603777.
Maassarani, Mahmoud El. "Identification de gènes cibles d'ErbB380kDa et caractérisation de leur implication au cours de la progression du cancer de la prostate." Thesis, Poitiers, 2014. http://www.theses.fr/2014POIT2275/document.
Prostate cancer (PCa) is dependent on androgens and functional androgen-receptor (AR) for growth and proliferation. Androgen-directed therapy is used at the first stages of the disease but cancer cells frequently become resistant (CRPC) by inappropriate reactivation of AR activity. As ErbB receptors are expressed in PCa cells, therapies aiming at inactivate the pathways downstream have been tested in advanced prostate cancers alongside hormone-based therapy. Still, a significant proportion of CRPC treated by ErbB1/2 inhibitors resist to treatment. ErbB3 could be responsible for this failure through both its unexpected nuclear localization and the reactivation of the PI3K-Akt pathway in those advanced tumors.We have described a nuclear ErbB380kDa isoform, expressed in hormone-sensitive (LNCaP) and hormone-resistant (PC3) PCa cell lines that accumulates in the nucleus of tumor cells during cancer progression. ChIP-on-chip experiments led us to characterize 353 target promoters binding ErbB380kDa in both cell lines; 245 promoters specific to LNCaP and 925 specific to PC3 cells, among which the promoter of GATA2. We show that ErbB380kDa functions as a transcriptional co-regulator for the studied genes, potentially through its interaction with transcription factors. In silico analysis revealed binding sites for GATA2 and MZF1 transcription factors on the target promoters, and a complex GATA2-MZF1-ErbB380kDa has been found in LNCaP and PC3 cells. Recent publications have reported a role for GATA2 in the regulation of RA responsive-genes and in metastatic spreading. We propose that ErbB380kDa could act, upstream of GATA2, to induce resistance mechanisms and facilitate cancer progression. Thus, ErbB380kDa emerges as a putative target for the development of new therapies in prostate cancer
Alexander, Frank. "RTEMIS: Real-Time Tumoroid and Environment Monitoring Using Impedance Spectroscopy and pH Sensing." Scholar Commons, 2014. https://scholarcommons.usf.edu/etd/5168.
Han, Arum. "Microfabricated Multi-Analysis System for Electrophysiological Studies of Single Cells." Diss., Georgia Institute of Technology, 2005. http://hdl.handle.net/1853/11639.
Veith, Irina. "Lung Cancer On-Chip for Immunotherapy Response Profiling Apoptosis Mapping in Space and Time of 3D Tumor Ecosystems Reveals Transmissibility of Cytotoxic Cancer Death." Thesis, université Paris-Saclay, 2020. http://www.theses.fr/2020UPASL036.
Non-small cell lung cancer (NSCLC) is one of the few tumor diseases, with melanoma and vesical carcinoma, for which immuno-oncology drugs led to a therapeutic revolution. Only 20 to 30% of the NSCLC patients benefit from immune checkpoint inhibitors (ICI) monotherapy with durable responses, while combinations led up to 40% of long responder patients. Our study aims to better characterize the modulation of the tumor microenvironment upon ICI treatment, plus or minus concurrent chemotherapy, in order to guide more compelling immunotherapy strategies. Inspired by the organ-on-a-chip technology, we implemented the reconstitution ex vivo of a simplified immunocompetent lung tumor microenvironment by performing 3D co-cultures in microfluidic devices. This approach allowed us to perform live-imaging and quantification of the effects of ICI on the tumor ecosystem.The design of the chip consists of three parallel micro-chambers, separated by micro-pillars that allow the confinement of a biomimetic hydrogel in the central channel by capillarity. By co-culturing autologous NSCLC cells and cytotoxic T lymphocytes (harvested from the TILs of the same patient and furtherly amplified in vitro) we could recapitulate, visualize and quantify an efficient and specific cytotoxic activity of the T cells against the autologous cancer cells. For this purpose, we developed a novel algorithm that could localize the cancer cells and, thanks to a fluorescent reporter of the caspase activity, measure their death in a time- and space-specific manner. In these 3D co-cultures the cytotoxic activity of T cells was enhanced by the treatment with PD-1 inhibitor and PD-L1 inhibitor, therefore reconstituting on-chip an ICI response. Furthermore, this method allowed us to extract a parameter, the potential of death induction, which mathematically estimates the “contagiousness of death” by computing the proximity in space and time of death signals. Interestingly, this analysis revealed us that the death of cancer cells caused by either chemotherapy or cytotoxic T cells is contagious, whereas in control conditions the cancer cells death is stochastic. This observation may have biological and clinical implications, for instance regarding the bystander effect, observed after radiotherapy treatment. Furthermore, in order to have a molecular insight on the impact of the co-culture on T cells, in presence or absence of ICI, we analyzed by flow cytometry the expression of several T cell markers. After 3 days of co-culture on chip, the T cells showed an increased expression of activation markers, such as CD69 and CD25, as well as an increased expression of exhaustion markers, notably PD-1, TIGIT, TIM-3, LAG-3, CD137 and OX-40. The coupling of image analysis and the study of T cell plasticity, allowed us to associate for the first time the finely quantified cytotoxic activity of the T cells and their activation/exhaustion status and describe a responsive phenotype to immunotherapies. In this thesis, we demonstrated that the tumor-on-chip is suitable to evaluate the efficacy of immune checkpoint inhibitors, to potentially assess the effect of combined drugs and to study the mechanisms of cancer cell primary resistance
Browne, Andrew W. "Translational Lab-on-a-Chips with the Development of a Novel Cancer Screening Method." University of Cincinnati / OhioLINK, 2010. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1275659036.
Salmanzadehdozdabi, Alireza. "Microfluidic differentiation of subpopulations of cells based on their bioelectrical signature." Diss., Virginia Tech, 2013. http://hdl.handle.net/10919/19370.
Microfluidics devices were engineered for differentiation of subpopulations of cells based on their bioelectrical properties. These microdevices were utilized for separating prostate, leukemia, and three different stages of breast cancer cells from hematologic cells with concentrations as low as 1:106 with efficiency of >95%. The microfluidic platform was also utilized to isolate prostate cancer stem cells (CSCs) from normal cancer cells based on their electrical signature. Isolating these cells is the first step towards the development of cancer specific therapies. The signal parameters required to selectively isolate ovarian cancer cells at different cancer stages were also compared with peritoneal cells as the first step in developing an early diagnostic clinical system centered on cell biophysical properties. Moreover, the effect of non-toxic concentrations of two metabolites, with known anti-tumor and pro-tumor properties, on the intrinsic electrical properties of early and late stages of ovarian cancer cells was investigated. This work is the first to show that treatment with non-toxic doses of these metabolites correlate with changes in cells electrical properties.
Ph. D.
Saint-Auret, Gaëlle. "Identification de la signature moléculaire de C/EBPβ dans la cellule d'hépatome humain Hep3B." Rouen, 2008. http://www.theses.fr/2008ROUES057.
The liver plays an essential part in complex metabolic regulations which widely contribute to the body homeostasis. Moreover, this organ conducts the qualitative and quantitative changes in the production of specific proteins immediately induced during the acute phase response and allowing a progressive come back to homeostasis. The liver-enriched transcription factor CCAAT enhancer-binding protein beta (C/EBPβ) is widely involved in these processes, but its precise the role isnot still defined. Conflicting studies have described contradictory functions for this transcription factor which could be explained by the complex mechanisms regulating the C/EBPβ activity. Indeed, C/EBPβ encodes an intronless gene that generates a single mRNA that is alternatively translated into two major isoforms : an active LAP (liver-enriched activator protein) and a dominant negative LIP (liver-enriched inhibitory protein). Today, few studies have really taken into account the present isoform. In order to better understand the precise role of each isoform, we first engineered the Hep3B human hepatoma cell line with a Tet-off inducible LAP or LIP isoform. The antagonistic role of the both isoforms in C/EBPβ target-genes transcription has been used as a strategy to better define the C/EBPβ-regulated genes. Then, the identity and the transcription (direct or indirect) of all these target-genes were determined by two functional genomic approaches : the transcriptome analysis by cDNA arrays and the chromatine immunoprecipitation on chip (ChIP on chip). Using a cDNA microarray which provides a complete coverage of the liver transcriptome, we identified 676 genes inversely regulated by LAP and LIP in the Hep3B hepatoma line. The analysis of the biological functions regulated by these genes brought into the flore an induction by LAP and a repression by LIP of several pathways including hepatic metabolism (fat, detoxification), transcription, translation, apoptosis and regulation of the cell proliferation. Moreover, the ChIP on chip study allowed the identification of 38 C/EBPβ new direct targets. According to the data resulting from the transcriptome analysis, several functional studies have been carried out. They allowed us to prove, for the first time, that LAP was, not only able to suppress the cell proliferation in the absence of RB and P53, but that this isoform also increased the staurosporine-induced apoptosis in Hep3B cells while LIP had a protector effect. Furthermore, the Hep3B cells expressing LAP or LIP have been stimulated by a conditioned medium rich in proinflammatory cytokines in order to mimic the hepatic response to the acute phrase of inflammation. In this experimental context, and still by transcriptome analysis, we brought into the fore a group of 77 genes regulated by LAP and LIP which interestingly seem to be involved during the acute phrase response. To conclude, our original approach characterized by the identification of genes inversely regulated by LAP and LIP allowed us to better understand how these two isoforms of C/EBPβ manage several physiological and pathological liver processes
Ahmad-Cognart, Hamizah. "Study of the Metastatic Process of Circulating Tumour Cells by Organ-on-a-Chip In Vitro Models." Thesis, Sorbonne Paris Cité, 2018. http://www.theses.fr/2018USPCC139/document.
90% of cancer mortality arises from metastases, due to cells that escape from a primary tumor, circulate in the blood as circulating tumor cells (CTCs), leave blood vessels and nest in distant organs. The processes by which CTCs invade distant organs, remodel their environment to create a “micrometastatic niche”, the eventual triggering of a proliferation leading to a macroscopic metastases, are poorly known, mostly because of a lack of experimental models. These events are rare; occur in the body at unknown places and on a microscopic scale. The loss of cell adhesion of tumor cells detaching from the primary tumor tissues will undergo a transformation phenomenon known as epithelial-to mesenchymal transition (EMT) leading to the loss of epithelial characteristics with different expression patterns of EMT markers (E-cadherin, N-cadherin, Vimentin, Snail1/2, Twist1/2, ZEB1/2). The changes in mechanical and physical properties of interacting cells during morphological and malignant transformation are investigated and their quantifications measured. Here, microfluidic models containing mechanical constrictions in order to mimic the blood microcirculation have been designed and fabricated. Metastatic breast cancer cells are subjected and confined to the microfluidic channels using a flow control system. These cells are circulated under optimal culture conditions, and monitored in the channels for the observance of biophysical occurrences from continuous mechanical cellular deformations. The biophysical effects of circulation and confinement on tumor cell morphogenesis will be investigated
Baka, Zakaria. "Élaboration de cancers sur puce pour des applications en thérapies anticancéreuses." Electronic Thesis or Diss., Université de Lorraine, 2023. http://www.theses.fr/2023LORR0175.
Ovarian cancer is a major public health issue. Moreover, new treatments still face very high failure rates. This is mainly due to the unreliability of conventional preclinical models such as 2D cell culture. Thus, new tools based on 3D cell culture have emerged such as spheroids and organoids. However, these models have their own limitations (cost, difficulty of application). 3D bioprinting is a new approach to create tunable and reproducible tumor models. However, very few bioprinted tumor models have been reported so far. Besides the “third dimension”, it is important to consider the dynamic conditions of the tumor environment. This has been possible for some years now thanks to microfluidics-based cancer-on-a-chip technology. However, this technology currently does not simulate the drug vascular transport before its interaction with the tumor cells. In this PhD project, we set out to create a dynamic, three-dimensional model of ovarian cancer by combining 3D bioprinting and microfluidics. First, 3D bioprinting was used to create the tumor structure itself. For that, we formulated a bio-ink comprising SKOV-3 ovarian cancer cells and MeWo cancer fibroblasts embedded in a gelatin – alginate hydrogel. The bioprinted tumor structures were then characterized by various techniques to demonstrate their viability and biological relevance. Their response to anticancer drug cisplatin was also assessed. In the second step, we integrated the bioprinted tumor model into a microfluidic support for culture under physiological flow. This support was also intended to simulate the drug's vascular transport prior to interaction with the tumor tissue. We then used computational fluid dynamics to design an improved version of the first system. The aim of this improved version was to simultaneously assess multiple drug concentrations. This PhD project demonstrated the ability of 3D bioprinting to create viable and functional ovarian tumor models. It has also brought interesting research prospects with regard to the possibilities of combining 3D bioprinting and microfluidics to improve preclinical modeling of ovarian tumors
Books on the topic "Cancer-On-Chip":
Segal, Ester, and Pranjal Chandra. Nanobiosensors for Personalized and Onsite Biomedical Diagnosis. Institution of Engineering & Technology, 2016.
Book chapters on the topic "Cancer-On-Chip":
Tong, Ziqiu, Wing-Yin Tong, Bo Peng, Yingkai Wei, Arianna Oddo, and Nicolas H. Voelcker. "Using Integrated Cancer-on-Chip Platforms to Emulate and Probe Various Cancer Models." In Nanotechnology Characterization Tools for Tissue Engineering and Medical Therapy, 151–204. Berlin, Heidelberg: Springer Berlin Heidelberg, 2019. http://dx.doi.org/10.1007/978-3-662-59596-1_4.
Caballero, David, Rui L. Reis, and Subhas C. Kundu. "Engineering Patient-on-a-Chip Models for Personalized Cancer Medicine." In Advances in Experimental Medicine and Biology, 43–64. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-36588-2_4.
Ho-Pun-Cheung, Alexandre, Hafid Abaibou, Philippe Cleuziat, and Evelyne Lopez-Crapez. "Detection of Single-Nucleotide Polymorphisms in Cancer-Related Genes by Minisequencing on a Microelectronic DNA Chip." In Microarrays, 267–78. Totowa, NJ: Humana Press, 2007. http://dx.doi.org/10.1007/978-1-59745-303-5_13.
Yang, Yamin, and Hongjun Wang. "Microfluidic Technologies for Head and Neck Cancer: From Single-Cell Analysis to Tumor-on-a-Chip." In Early Detection and Treatment of Head & Neck Cancers, 43–62. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-69859-1_3.
Parihar, Arpana, Nishant Kumar Choudhary, Dipesh Singh Parihar, and Raju Khan. "Tumor-on-a-Chip: Microfluidic Models of Hypoxic Tumor Microenvironment." In Hypoxia in Cancer: Significance and Impact on Cancer Therapy, 297–328. Singapore: Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-99-0313-9_14.
Lopez-Muñoz, Gerardo A., Sheeza Mughal, and Javier Ramón-Azcón. "Correction to: Sensors and Biosensors in Organs-on-a-Chip Platforms." In Microfluidics and Biosensors in Cancer Research, C1. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-04039-9_23.
Li, Caiwei, Jiao Zhai, and Yanwei Jia. "Digital Microfluidics with an On-Chip Drug Dispenser for Single or Combinational Drug Screening." In Microfluidic Systems for Cancer Diagnosis, 25–39. New York, NY: Springer US, 2023. http://dx.doi.org/10.1007/978-1-0716-3271-0_3.
Mu, Xuan, and Yu Shrike Zhang. "Tumor-on-a-chip devices for cancer immunotherapy." In Engineering Technologies and Clinical Translation, 155–95. Elsevier, 2022. http://dx.doi.org/10.1016/b978-0-323-90949-5.00006-1.
Anton Okhai, Timothy, Azeez O. Idris, Usisipho Feleni, and Lukas W. Snyman. "Nanomaterial-Enhanced Receptor Technology for Silicon On-Chip Biosensing Application." In Biosensor - Current and Novel Strategies for Biosensing [Working Title]. IntechOpen, 2020. http://dx.doi.org/10.5772/intechopen.94249.
Firoozbakhtian, Ali, Morteza Hosseini, Javad Gilnezhad, and Mohammad Reza Ganjali. "Lab-on-a-chip systems for aptamer-based cancer biomarker screening." In Aptasensors for Point-of-Care Diagnostics of Cancer, 9–1. IOP Publishing, 2023. http://dx.doi.org/10.1088/978-0-7503-5012-9ch9.
Conference papers on the topic "Cancer-On-Chip":
Liao, Han-Jung, Jean-An Chieh, Yu-Chen Chen, Kang-Yun Lee, Yao-Fei Chan, Shu-Chuan Ho, Wei-lun Sun, et al. "Lung Cancer On Chip for Testing Immunotherapy." In 2021 21st International Conference on Solid-State Sensors, Actuators and Microsystems (Transducers). IEEE, 2021. http://dx.doi.org/10.1109/transducers50396.2021.9495530.
Chang, Kuo-Wei, Tushar Harishchandra Punde, Gaurav Prashant Pendharkar, Po-Chen Shih, Yao-Fei Chan, Kang-Yun Lee, Ming-Yan Chen, and Cheng-Hsien Liu. "Lung cancer model on chip for drug testing." In TRANSDUCERS 2015 - 2015 18th International Solid-State Sensors, Actuators and Microsystems Conference. IEEE, 2015. http://dx.doi.org/10.1109/transducers.2015.7181006.
Darabi, Jeff, and Joseph Schober. "A Microfluidic Platform for On-Chip Analysis of Circulating Tumor Cells." In ASME 2021 Fluids Engineering Division Summer Meeting. American Society of Mechanical Engineers, 2021. http://dx.doi.org/10.1115/fedsm2021-65766.
Pradhan, Shantanu, Ashley M. Smith, Charles J. Garson, Iman Hassani, Kapil Pant, Robert D. Arnold, Balabhaskar Prabhakarpandian, and Elizabeth A. Lipke. "Abstract 620: Microfluidic cancer-on-a-chip platform for assessing anti-cancer drug efficacies." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-620.
Wan, Yuan, Young-tae Kim, Li Na, Andrew D. Ellington, and Samir M. Iqbal. "Aptamer-Based Lab-on-Chip for Cancer Cell Isolation and Detection." In ASME 2010 First Global Congress on NanoEngineering for Medicine and Biology. ASMEDC, 2010. http://dx.doi.org/10.1115/nemb2010-13195.
Sala, Federico. "On-Chip high-throughput LSFM analysis of single cancer cells." In Virtual 12th Light Sheet Fluorescence Microscopy Conference 2020. Royal Microscopical Society, 2020. http://dx.doi.org/10.22443/rms.lsfm2020.27.
Lee, Wonjun, Jiin Park, Dongil Kang, and Seungbeum Suh. "Reconstituting Fundamentals of Bacteria Mediated Cancer Therapy On A Chip." In 2023 IEEE 36th International Conference on Micro Electro Mechanical Systems (MEMS). IEEE, 2023. http://dx.doi.org/10.1109/mems49605.2023.10052432.
Picollet-D'hahan, N., B. Laperrousaz, S. Porte, P. Obeid, A. Tollance, F. Kermarrec, C. Belda-Marin, et al. "Encapsulated organoids & organ-on-a-chip platform for cancer modeling." In 2017 IEEE International Electron Devices Meeting (IEDM). IEEE, 2017. http://dx.doi.org/10.1109/iedm.2017.8268366.
Vieira, Dalila, Filipa Mata, Ana Moita, and António Moreira. "Microfluidic Prototype of a Lab-on-Chip Device for Lung Cancer Diagnostics." In 10th International Conference on Biomedical Electronics and Devices. SCITEPRESS - Science and Technology Publications, 2017. http://dx.doi.org/10.5220/0006252700630068.
Gopal, Ashwini, Zhiguo Wang, Kazunori Hoshino, and Ziaozjing Zhang. "Multispectral analysis of cancer cells using quantum dot leds patterned on-chip." In TRANSDUCERS 2011 - 2011 16th International Solid-State Sensors, Actuators and Microsystems Conference. IEEE, 2011. http://dx.doi.org/10.1109/transducers.2011.5969745.